Conference Proceedings
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: A North American brain tumor consortium study
TF Cloughesy, J Kuhn, HI Robins, L Abrey, P Wen, K Fink, FS Lieberman, M Mehta, S Chang, A Yung, L DeAngelis, D Schiff, L Junck, M Groves, S Paquette, J Wright, K Lamborn, SM Sebti, M Prados
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2005
Abstract
PURPOSE: To determine the maximum-tolerated dose (MTD), toxicities, and clinical effect of tipifarnib, a farnesyltransferase (FTase) inhibitor, in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs). This study compares the pharmacokinetics and pharmacodynamics of tipifarnib at MTD in patients on and off EIAEDs. PATIENTS AND METHODS: Recurrent malignant glioma patients were treated with tipifarnib using an interpatient dose-escalation scheme. Pharmacokinetics and pharmacodynamics were assessed. RESULTS: Twenty-three assessable patients taking EIAEDs received tipifarnib in escalating doses from 300 to 700 mg bid for 21 of 28 days. The dose-limiting tox..
View full abstractGrants
Awarded by NCI NIH HHS
Awarded by NCRR NIH HHS
Awarded by NATIONAL CANCER INSTITUTE
Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES